MDNU Medical Nutrition Usa (MM)

Medical Nutrition USA, Inc. (NASDAQ: MDNU), a developer and distributor of uniquely engineered, nutrition-medicine products, announced the introduction of Diff-Stat(TM), a new supplement containing pre- and probiotics to help restore and maintain beneficial bacteria that prevent the onset of antibiotic-associated diarrhea (AAD) and clostridium difficile (C-diff).

C-diff is a bacterium that causes diarrhea and more serious intestinal conditions. It is one of the chief causes of hospital-acquired diarrhea in the U.S., responsible for approximately three million cases per year of diarrhea and colitis treated at an annual cost of more than $1.1 billion.(1)

Both C-diff and AAD pose serious risks to the health of elderly and frail patients from the wasting effects of diarrhea and intestinal damage. The likelihood that such conditions will arise in this population is increased when patients take antibiotics, which can eliminate the beneficial intestinal microbiota that help prevent the onset of AAD and C-diff.

Diff-Stat(TM), which is available as a powder or as a chewable tablet, contains a combination of clinically proven ingredients that help combat the effects of antibiotics on intestinal microbiota by providing increased beneficial bacteria to the colon, destroying toxins and toxin binding sites and stimulating the growth of beneficial bacteria.

Strong results in patients on antibiotic regimens

A recently completed survey of 82 residents taking Diff-Stat(TM) while undergoing antibiotic therapy at 17 long-term care facilities showed that 96 percent of the survey population did not develop AAD and 100 percent did not develop C-diff during, and after completing, antibiotic therapy. Participants were given one chewable tablet twice daily within three days of starting antibiotic therapy and continuing for two weeks after completing antibiotic therapy.

Other notable outcomes of the survey included an overwhelming response (99 percent) from clinicians that Diff-Stat(TM) was easy to administer, and that patient compliance and taste acceptability were good.

"Diff-Stat(TM) was developed in response to clinicians' concerns about the prevalent incidence of AAD and C-diff in the long-term care and acute care facilities that make up Medical Nutrition's primary market," said Frank A. Newman, Medical Nutrition's Chairman and Chief Executive Officer. "Diff-Stat is further evidence of our company's continuing ability to develop effective new products that address clinicians' needs in easy-to-administer and cost-effective forms."

"As with our prior industry-first products such as Pro-Stat®, UTI-Stat(TM) and Pro-Stat® AWC (Advanced Wound Care), Diff-Stat(TM) expands the therapeutic options available to clinicians while creating a new revenue stream that we expect will grow significantly as institutions come to rely upon the products' effectiveness and ease of administration."

(1) Blossom DB, McDonald C.; The Challenges Posed by Reemerging Clostridium Difficile Infection. CID. 2007; 45:222-227.

About Medical Nutrition USA, Inc.

Medical Nutrition USA develops and distributes products for the nutritionally at risk who are under medical supervision. Its products are used primarily in long-term care facilities, hospitals, dialysis clinics and bariatric clinics. The Company's product lines include Pro-Stat®, Fiber-Stat® and UTI-Stat(TM), as well as private label products. Additional information is available at www.mdnu.com.

This news release contains forward-looking statements that are subject to certain risks and uncertainties. Although we believe that the expectations reflected in any of our forward-looking statements are reasonable, actual results could differ materially from those projected or assumed. Risks and uncertainties that could cause or contribute to such material difference include, but are not limited to, general economic conditions, changes in customer demand, changes in trends in the nursing home, renal care, health food and bariatric surgery markets, changes in competitive pricing for products, and the impact of our competitors' new product introductions. Our future financial condition and results of operations, as well as any forward-looking statements are subject to change and inherent risk and uncertainties. Other important factors that may cause actual results to differ materially from those expressed in forward-looking statements is contained in the Medical Nutrition USA, Inc. Annual Report on Form 10-K for the year ended January 31, 2009 as filed with the Securities and Exchange Commission on April 24, 2009 and Form 10-Q for the quarter ended July 31, 2009 filed on Sept. 11, 2009.

Contacts: Medical Nutrition USA, Inc. Frank J. Kimmerling Vice President/CFO 800.221.0308 Email Contact Investor Relations Adam Friedman 212.981.2529 x18 Email Contact